共 188 条
[1]
Bajetta E(2004)Randomized multicenter phase II trial of two different schedules of irinotecan combined to capecitabine as first line treatment in metastatic colorectal cancer Cancer 100 279-287
[2]
Di Bartolomeo M(2004)XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 2084-2091
[3]
Mariani L(2009)A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC) [abstract e15019] J Clin Oncol ASCO Annu Meet Proc 27 e15019-690
[4]
Cassata A(2009)Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) [abstract 4086] J Clin Oncol ASCO Annu Meet Proc 27 4086-4786
[5]
Artale S(2008)Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study J Clin Oncol 26 689-1043
[6]
Frustaci S(2007)Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 4779-2292
[7]
Pinotti G(2009)Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group Br J Cancer 101 1039-2342
[8]
Bonetti A(2001)Comparison of oral capecitabine J Clin Oncol 19 2282-481
[9]
Carreca I(2004) intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III trial N Engl J Med 350 2335-926
[10]
Biasco G(1958)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer J Am Stat Assoc 53 457-98